Investors who purchased shares of Viropharma Inc (NASDAQ:VPHM)
The investigation by a law firm focuses on whether a series of statements made between December 14, 2011 and April 9, 2012, inclusive, regarding ViroPharma's business, its prospects and its operations were materially false and misleading at the time they were made. Specifically, the investigation seeks to determine, among other things, whether ViroPharma knew but failed to adequately and timely disclose that its sNDA for Vancocin did not provide for any significant new use or indication for the drug and, as a result, Vancocin would not be eligible to receive an additional three years of exclusivity.
On April 10, 2012, ViroPharma Incorporated (Nasdaq: VPHM) announced the U.S. Food and Drug Administration (“FDA”) denied the citizen petition filed by ViroPharma on March 17, 2006 related to the FDA's proposed in vitro method for determining bioequivalence of abbreviated new drug applications (ANDAs) referencing Vancocin® (vancomycin hydrochloride, USP) Capsules.
Shares of Viropharma Inc (NASDAQ:VPHM)
On May 11, 2012 NASDAQW:VPHM shares closed at $20.67 per share.
Those who purchased shares of Viropharma Inc (NASDAQ:VPHM)